AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.

AKI is a common sequela of coronavirus disease 2019 (COVID-19). However, few studies have focused on AKI treated with RRT (AKI-RRT). We conducted a multicenter cohort study of 3099 critically ill adults with COVID-19 admitted to intensive care units (ICUs) at 67 hospitals across the United States. We used multivariable logistic regression to identify patient-and hospital-level risk factors for AKI-RRT and to examine risk factors for 28-day mortality among such patients. A total of 637 of 3099 patients (20.6%) developed AKI-RRT within 14 days of ICU admission, 350 of whom (54.9%) died within 28 days of ICU admission. Patient-level risk factors for AKI-RRT included CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index, higher d-dimer, and greater severity of hypoxemia on ICU admission. Predictors of 28-day mortality in patients with AKI-RRT were older age, severe oliguria, and admission to a hospital with fewer ICU beds or one with greater regional density of COVID-19. At the end of a median follow-up of 17 days (range, 1-123 days), 403 of the 637 patients (63.3%) with AKI-RRT had died, 216 (33.9%) were discharged, and 18 (2.8%) remained hospitalized. Of the 216 patients discharged, 73 (33.8%) remained RRT dependent at discharge, and 39 (18.1%) remained RRT dependent 60 days after ICU admission. AKI-RRT is common among critically ill patients with COVID-19 and is associated with a hospital mortality rate of >60%. Among those who survive to discharge, one in three still depends on RRT at discharge, and one in six remains RRT dependent 60 days after ICU admission.

Gupta S ，Coca SG ，Chan L ，Melamed ML ，Brenner SK ，Hayek SS ，Sutherland A ，Puri S ，Srivastava A ，Leonberg-Yoo A ，Shehata AM ，Flythe JE ，Rashidi A ，Schenck EJ ，Goyal N ，Hedayati SS ，Dy R ，Bansal A ，Athavale A ，Nguyen HB ，Vijayan A ，Charytan DM ，Schulze CE ，Joo MJ ，Friedman AN ，Zhang J ，Sosa MA ，Judd E ，Velez JCQ ，Mallappallil M ，Redfern RE ，Bansal AD ，Neyra JA ，Liu KD ，Renaghan AD ，Christov M ，Molnar MZ ，Sharma S ，Kamal O ，Boateng JO ，Short SAP ，Admon AJ ，Sise ME ，Wang W ，Parikh CR ，Leaf DE ，and the STOP-COVID Investigators ... -  《-》

Acute Kidney Injury and Renal Replacement Therapy in Critically Ill COVID-19 Patients: Risk Factors and Outcomes: A Single-Center Experience in Brazil.

Critically ill patients with COVID-19 may develop multiple organ dysfunction syndrome, including acute kidney injury (AKI). We report the incidence, risk factors, associations, and outcomes of AKI and renal replacement therapy (RRT) in critically ill COVID-19 patients. We performed a retrospective cohort study of adult patients with COVID-19 diagnosis admitted to the intensive care unit (ICU) between March 2020 and May 2020. Multivariable logistic regression analysis was applied to identify risk factors for the development of AKI and use of RRT. The primary outcome was 60-day mortality after ICU admission. 101 (50.2%) patients developed AKI (72% on the first day of invasive mechanical ventilation [IMV]), and thirty-four (17%) required RRT. Risk factors for AKI included higher baseline Cr (OR 2.50 [1.33-4.69], p = 0.005), diuretic use (OR 4.14 [1.27-13.49], p = 0.019), and IMV (OR 7.60 [1.37-42.05], p = 0.020). A higher C-reactive protein level was an additional risk factor for RRT (OR 2.12 [1.16-4.33], p = 0.023). Overall 60-day mortality was 14.4% {23.8% (n = 24) in the AKI group versus 5% (n = 5) in the non-AKI group (HR 2.79 [1.04-7.49], p = 0.040); and 35.3% (n = 12) in the RRT group versus 10.2% (n = 17) in the non-RRT group, respectively (HR 2.21 [1.01-4.85], p = 0.047)}. AKI was common among critically ill COVID-19 patients and occurred early in association with IMV. One in 6 AKI patients received RRT and 1 in 3 patients treated with RRT died in hospital. These findings provide important prognostic information for clinicians caring for these patients.

Doher MP ，Torres de Carvalho FR ，Scherer PF ，Matsui TN ，Ammirati AL ，Caldin da Silva B ，Barbeiro BG ，Carneiro FD ，Corrêa TD ，Ferraz LJR ，Dos Santos BFC ，Pereira VG ，Batista MC ，Monte JCM ，Santos OFP ，Bellomo R ，Serpa Neto A ，Durão MS ... -  《-》

Characterization of hospitalized patients with acute kidney injury associated with COVID-19 in Spain: renal replacement therapy and mortality. FRA-COVID SEN Registry Data.

Acute kidney injury (AKI) is common among hospitalized patients with COVID-19 and associated with worse prognosis. The Spanish Society of Nephrology created the AKI- COVID Registry to characterize the population admitted for COVID-19 that developed AKI in Spanish hospitals. The need of renal replacement therapy (RRT) therapeutic modalities, and mortality in these patients were assessed MATERIAL AND METHOD: In a retrospective study, we analyzed data from the AKI-COVID Registry, which included patients hospitalized in 30 Spanish hospitals from May 2020 to November 2021. Clinical and demographic variables, factors related to the severity of COVID-19 and AKI, and survival data were recorded. A multivariate regression analysis was performed to study factors related to RRT and mortality. Data from 730 patients were recorded. A total of 71.9% were men, with a mean age of 70 years (60-78), 70.1% were hypertensive, 32.9% diabetic, 33.3% with cardiovascular disease and 23.9% had some degree of chronic kidney disease (CKD). Pneumonia was diagnosed in 94.6%, requiring ventilatory support in 54.2% and admission to the ICU in 44.1% of cases. The median time from the onset of COVID-19 symptoms to the appearance of AKI (37.1% KDIGO I, 18.3% KDIGO II, 44.6% KDIGO III) was 6 days (4-10). A total of 235 (33.9%) patients required RRT: 155 patients with continuous renal replacement therapy, 89 alternate-day dialysis, 36 daily dialysis, 24 extended hemodialysis and 17 patients with hemodiafiltration. Smoking habit (OR 3.41), ventilatory support (OR 20.2), maximum creatinine value (OR 2.41), and time to AKI onset (OR 1.13) were predictors of the need for RRT; age was a protective factor (0.95). The group without RRT was characterized by older age, less severe AKI, and shorter kidney injury onset and recovery time (p < 0.05). 38.6% of patients died during hospitalization; serious AKI and RRT were more frequent in the death group. In the multivariate analysis, age (OR 1.03), previous chronic kidney disease (OR 2.21), development of pneumonia (OR 2.89), ventilatory support (OR 3.34) and RRT (OR 2.28) were predictors of mortality while chronic treatment with ARBs was identified as a protective factor (OR 0.55). Patients with AKI during hospitalization for COVID-19 had a high mean age, comorbidities and severe infection. We defined two different clinical patterns: an AKI of early onset, in older patients that resolves in a few days without the need for RRT; and another more severe pattern, with greater need for RRT, and late onset, which was related to greater severity of the infectious disease. The severity of the infection, age and the presence of CKD prior to admission were identified as a risk factors for mortality in these patients. In addition chronic treatment with ARBs was identified as a protective factor for mortality.

Salgueira M ，Almenara M ，Gutierrez-Pizarraya A ，Belmar L ，Labrador PJ ，Melero R ，Serrano M ，Portolés JM ，Molina A ，Poch E ，Ramos N ，Lloret MJ ，Echarri R ，Díaz-Mancebo R ，González-Lara DM ，Sánchez JE ，Soler MJ ... -  《-》

Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study.

Lowe R ，Ferrari M ，Nasim-Mohi M ，Jackson A ，Beecham R ，Veighey K ，Cusack R ，Richardson D ，Grocott M ，Levett D ，Dushianthan A ，University Hospital Southampton Critical Care Team and the REACT COVID investigators ... -  《BMC Nephrology》

COVID-19-associated acute kidney injury patients treated with renal replacement therapy in the intensive care unit: A multicenter study in São Paulo, Brazil.

Samaan F ，Carneiro de Paula E ，de Lima Souza FBG ，Mendes LFC ，Rossi PRG ，Freitas RAP ，Nakagawa FT ，Maciel AT ，Aranha S ，Osawa E ，Konigsfeld HP ，da Silva RG ，de Souza RBC ，Coutinho SM ，Vieira TD ，Thomaz KB ，Flato EMS ，da Silva RC ，Andrade LV ，Badaoui M ，Badaoui EP ，Goes MÂ ，do Amaral SH ，Cunha K ，Muniz IM ，Sampaio JS ，Durão Junior MS ，Zanetta DMT ，Burdmann EA ... -  《PLoS One》